ETIDIOH - NEW

Abstract Several concurrent mpox outbreaks are ongoing in the Democratic Republic of the Congo . We report a case of severe clade Ia mpox in an adult woman with indeterminate HIV status who died 16 days after symptom onset. She self-identified as a sex worker and had spent time in the capital city, Kinshasa. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/5/24-1690_article ____

Summary Background More than 115 000 cases of mpox have been confirmed since the onset of a global outbreak in 2022. In addition to global transmission of clade II monkeypox virus (MPXV), the recent spread of clade I has caused a Public Health Emergency of International Concern . The third-generation smallpox vaccine modified vaccinia Ankara–Bavarian Nordic (MVA-BN) was recommended for at-risk populations in 2022, despite a scarcity of data on safety and effectiveness against mpox. Methods We did a prospective, multicentre, observational study, enrolling men who have sex with men and transgender people aged 18 years or older with changing sexual partners in Germany (Safety and Effectiveness of MVA-BN Vaccination Against MPXV Infection [SEMVAc]) between July 7, 2022, and Dec 31, 2023, evaluating safety and reactogenicity of one and two doses of subcutaneous MVA-BN. Vaccine effectiveness was estimated using risk ratios from the Kaplan–Meier estimator in an emulated retrospective target t...

The Director-General of the World Health Organization (WHO) is hereby transmitting the report of the third meeting of the International Health Regulations (2005) (IHR) Emergency Committee (Committee) regarding the upsurge of mpox 2024, held on Tuesday, 25 February 2025, from 12:00 to 17:00 CET . Concurring with the advice unanimously expressed by the Committee during the meeting, the WHO Director-General determined that the upsurge of mpox 2024 continues to meet the criteria of a public health emergency of international concern (PHEIC) and, accordingly, on 27 February 2025, issued temporary recommendations to States Parties. The WHO Director-General expresses his most sincere gratitude to the Chair, Members, and Advisors of the Committee. Proceedings of the meeting Sixteen (16) Members of, and two Advisors to, the International Health Regulations (2005) (IHR) Emergency Committee (Committee) were convened by teleconference, via Zoom, on Tuesday, 25 February 2025, from 12:00 to 17:00 CET...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health (NIH).  The trial enrollment was stopped in late 2024 when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. “This study brought us a step forward in better understanding mpox disease and potential treatment strategies,” said Jeanne Marrazzo, M.D., M.P.H., director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), which sponsored and funded the trial. “We are grateful to the study team and participants for their contributions to groundbreaking research on a disease that we still do not know enough about.” Mpox is caused by a virus that spreads ...

{Excerpts} The Director-General of the World Health Organization (WHO), following the third meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the upsurge of mpox 2024, held on 25 February 2025, from 12:00 to 17:00 CET, concurs with its advice that the event continues to meet the criteria of a public health emergency of international concern and, considering the advice of the Committee, he is hereby issuing a revised set of temporary recommendations. The WHO Director-General expresses his most sincere gratitude to the Chair, Members, and Advisors of the Committee. The proceeding of the third meeting of the Committee will be shared with States Parties to the IHR and published in the coming days. --------- Temporary recommendations These temporary recommendations are issued to States Parties experiencing the transmission of monkeypox virus (MPXV), including, but not limited to, those where there is sustained community transmission, and where there ...

Abstract The COVID-19 pandemic has increased the interest in the use of wastewater-based surveillance (WBS) strategy for infectious disease monitoring, especially when clinical cases are underreported. The excretion of monkey virus (MPXV) in the feces of both symptomatic and preclinical individuals has further driven the interest in WBS applicability to MPXV monitoring in wastewater to support its mitigation efforts. We performed a systematic review with meta-analysis, using six databases to assess MPXV detection in wastewater. We performed a random-effects model meta-analysis to calculate the pooled prevalence at a 95% confidence interval (95% CI). Also, we carried out a subgroup analysis according to the country regions and a sensitivity analysis excluding studies classified as having a high risk of bias. The overall MPXV positivity rate in wastewater was estimated at 22% (95% CI: 14−30%; I2 = 94.8%), with more detection rate in North America (26%, 95% CI: 8–43%) compared to Europe a...

 {February 13 2025} Latest update A new case of clade Ib mpox has been detected in England, the UK Health Security Agency (UKHSA) can confirm .  The case was detected in London and the individual is now under specialist care at the Royal Free Hospital High Consequence Infectious Diseases unit. They had recently returned from Uganda , where there is currently community transmission of clade Ib mpox. The UKHSA and NHS will not be disclosing any further details about the individual. The risk to the UK population remains low . In the context of the outbreak in parts of Africa, we expect to see the occasional imported case of clade Ib mpox in the UK. This is the eighth case of clade Ib mpox confirmed in England since October 2024. This case has no links to the previous cases identified in England. Close contacts of the case are being followed up by UKHSA and partner organisations. Contacts will be offered testing and vaccination where needed to prevent further infections and they w...

Abstract Background For decades after the identification of mpox in humans in the Democratic Republic of Congo (DRC) in 1970, the disease was largely confined to the rural areas of Central and West Africa and thus did not garner broad attention. On August 13, 2024, mpox was declared a Public Health Emergency of Continental Security (PHECS) by the Africa Centers for Disease Control and Prevention (Africa CDC), a notice that was followed the next day by a declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization. Methods In this study we analyzed all mpox cases and deaths , based on clinical or laboratory diagnosis, that were reported to the Africa CDC from January 1, 2022, to October 30, 2024, to identify temporal variations, geographic distributions, and epidemiologic trends. Results From January 1, 2022, to August 18, 2024, a total of 45,652 mpox cases were clinically diagnosed and laboratory-confirmed in 12 African countries . These ca...

Juba, 7 February 2025—Today the Ministry of Health has declared a mpox outbreak in Juba, Central Equatoria State. This declaration follows a confirmation mpox Case by the National Public Health Laboratory on 6 February 2025 . “The first case was reported on 6 February 2025 at Gudele Hospital from a Ugandan national and a resident of Kupuri Camp in Juba. The confirmed case is under isolation and is being managed at Gudele Hospital”, said the Acting Health Minister, Honorable James Hoth Mai, in a press conference in Juba.  A team of experts from national and subnational levels , WHO, and other partners have been mobilized to conduct a detailed field investigation, list all contacts, and ensure close follow-up, Hon. Mai added. He also added that the Ministry of Health and WHO have taken steps to manage the reported case properly, ensuring that every contact on the ground is followed. He assured the citizens not to panic but to stay calm and follow safety measures that the government i...

Summary Background DR Congo has the highest global burden of mpox , a disease caused by infection with the monkeypox virus . The incidence has risen since 1980, but recent analyses of epidemiological trends are lacking. We aimed to describe trends in suspected and confirmed mpox cases in DR Congo using epidemiological and laboratory mpox surveillance data collected from 2010 to 2023, and provide insights that can better inform the targeting and monitoring of control strategies. Methods We analysed aggregated national epidemiological surveillance data and individual-level laboratory data from 2010 to 2023. We calculated incidence based on suspected cases, case-fatality ratios, and percentage of laboratory-confirmed cases and assessed geospatial trends. Demographic and seasonal trends were investigated using generalised additive mixed models. Findings Between Jan 1, 2010, and Dec 31, 2023, a total of 60 967 suspected cases and 1798 suspected deaths from mpox were reported in DR Congo ( c...

{Excerpt} The zoonotic Orthopoxvirus monkeypox virus includes two main clades (ie, 1 and 2) relevant to human transmission .1 Two major outbreaks of monkeypox virus have occurred since 2022,1–3 and were declared public health emergencies of international concern by WHO in July, 2022, and August, 2024. The first outbreak was caused by a clade 2b strain that quickly spread worldwide, resulting in approximately 100 000 cases and 200 deaths.3 In the second outbreak, the novel clade 1b emerged .4 As of December, 2024, this upsurge has resulted in more than 55 000 reported or suspected cases and approximately 1000 deaths in DR Congo and neighbouring countries, including Burundi, Rwanda, Uganda , and Angola .4 A few imported clade 1b cases have also been reported in the UK, Sweden, Germany, Belgium, France, the USA, Canada , and Thailand .5 Prevention measures include patient isolation and care as well as vaccines. (...) Source: Lancet Infectious Diseases,  https://www.thelancet.com/journ...

Abstract We previously reported that mice immunized twice with a lipid nanoparticle vaccine comprising four monkeypox viral mRNAs raised neutralizing antibodies and antigen-specific T cells and were protected against a lethal intranasal challenge with vaccinia virus (VACV). Here we demonstrated that the mRNA vaccine also protects mice against intranasal and intraperitoneal infections with monkeypox virus and bioluminescence imaging showed that vaccination greatly reduces or prevents VACV replication and spread from intranasal, rectal, and dermal inoculation sites. A single vaccination provided considerable protection that was enhanced by boosting for at least 4 months. Protection was related to the amount of mRNA inoculated, which correlated with neutralizing antibody levels . Furthermore, immunocompetent and immunodeficient mice lacking mature B and T cells that received serum from mRNA-immunized macaques before or after VACV challenge were protected. These findings provide insights i...